Rilmenidine provides antihypertensive efficacy comparable with that of diuretics, beta-blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors.
Rilmenidine (25-100 μM; 24 hours) inhibits K562 cell proliferation.
Cell Viability Assay
Cell Line: | K562 cells |
Concentration: | 25, 50, 100 μM |
Incubation Time: | 24 hours |
Result: | Dose-dependently inhibited K562 colony formation. |
Rilmenidine-treated N171-82Q mice (i.p.; 4-times a week) displays significant improved forelimb grip strength and all limbs grip strength from 12 to 22 weeks of age.
Rilmenidine decreases levels of mutant huntingtin.